Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.50p +1.65% 30.75p 30.00p 31.50p 30.75p 30.25p 30.25p 41,525 08:11:56
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -7.2 -4.5 - 63.00

Futura Medical Share Discussion Threads

Showing 16876 to 16898 of 16900 messages
Chat Pages: 676  675  674  673  672  671  670  669  668  667  666  665  Older
DateSubjectAuthorDiscuss
24/6/2019
16:33
So LO now buying into Silence therapeutics.
wantage
20/6/2019
19:08
Excellent progress after the pull back, I added at 21p... hopefully this one can follow (STX)which is I feel is ready for greatness next month fingers x’d
ny boy
20/6/2019
14:39
Not really when it is possibly worth 140p. Even that number from Liberum is based on numbers far lower than Futura has garnered from the likes of Ipsos. Futura "The potential market for this product is large with potential peak sales in excess of US $1 billion. If MED2005 is approved, there is an estimated $560M prescription-only market potential (sources: Decision Resources and Cello), and an estimated incremental $660M+ market potential as an over-the-counter (OTC) product, in markets where switch is possible. (source: Ipsos Mori forecasts commissioned by Futura)." Liberum we forecast a peak sales range of £230- 500m So if Futura is right then it follows the share price could be 280p not 140p. Food for thought
j777j
20/6/2019
13:50
Looks like LO stopped selling for the moment - Strange not to let a few more go in such a strong market.
wantage
20/6/2019
12:10
Simon Thompson - "I maintain my view that Futura’s share price has the potential to multiply many times over if the £62m market capitalisation company delivers the headline data that potential commercial partners are looking for."
cf456
20/6/2019
12:00
Now we realise why it hit 90p a couple of years back,on the prospects. It went from 14p to 90p in a month. It certainly puts the Liberum 140p in perspective as we have been close to that before. The huge difference is we are now within 5 months of phase 3 results I see this as serious multibagger.
j777j
20/6/2019
11:56
hTTps://www.investorschronicle.co.uk/comment/2019/06/20/futura-s-huge-potential-arouses-investor-interest/
cf456
20/6/2019
09:16
Excellent progress, stay patient as we head for 100p + next year. (SKIN) another one about to take off too dyor
ny boy
20/6/2019
08:45
From the Liberum report. "Under the Highly Successful scenario, we believe Futura is worth £1.40 per share, almost 8x its current value." Let's hope for that outcome.Meanwhile I expect a significant advance towards their current risk adjusted 60p share price. Also worth bearing in mind Liberum's sales forecasts are very conservative .
j777j
19/6/2019
16:13
mike whatever you paid I think you'll get your money back.Too many false dawns in this stock, and too little institutional presence but it looks like finally it's coming together.I think Liberum are now supporting it.At least we know what we're aiming for and we'll know by end of Dec we'll have conclusive results.Seems LO still selling - 175K sale lunchtime.
wantage
19/6/2019
14:18
if only CSD500 had had regular progress RNSs, like Med is now having, I wouldn't be sitting on a thumping loss on FUM like I am
mikethebike4
19/6/2019
12:18
I do rather like this sort of confidence from the Broker The broker added that the Phase 3 trial for MED2002 was “low-risk̶1; as the study currently had 20 realistic outcomes, only one of which would mean the treatment could not be launched commercially. As a result, Liberum said Futura’s current share price was a “very attractive entry-point” with even its risk-adjusted valuation pointing to upside in the shares of over 100%.
ragnarr
19/6/2019
11:20
https://www.proactiveinvestors.co.uk/companies/news/219194/futura-medical-looking-ahead-to-completion-of-key-phase-iii-ed-trial-219194.html ???
horneblower
19/6/2019
11:20
J777J I think you could be right. The main focus is obviously on MED2005 but there is definitely news due at some point re TPR100 TPR100 - topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism In July 2018, Thornton & Ross, a subsidiary of STADA AG, Futura's UK commercialisation partner for TPR100, filed a marketing authorisation application for the product with the UK Medicines and Healthcare products Regulatory Agency (MHRA). In February 2019, the MHRA responded with some questions requiring some additional laboratory studies which are in the process of being conducted in order to address the MHRA's questions and allow the submission to progress and complete the review process. Futura has ongoing commercial discussions with several potential distribution partners for territories outside of the UK. Finalisation of such regional licensing deals is expected to be after UK regulatory approval.
ragnarr
19/6/2019
10:48
Ken James sounds extremely chipper. Still in ongoing commercial negotiations. My hunch remains a deal maybe closer than many think.
j777j
19/6/2019
10:33
Proactive Investor Interview: Sorry - I am struggling to upload the link here.
alchemist1010
19/6/2019
09:24
Pleased to see recruitment completed on time and on budget, well done FUM.
rrr
19/6/2019
09:18
Should hopefully see a nice steady rise to maybe 35/40 over the coming months and assuming data is good at the end of the year the sky is the limit then
ragnarr
19/6/2019
07:49
Ties in nicely with this "Futura Medical PLC’s (LON:FUM) data from a Phase 3 trial of its MED2005 erectile dysfunction treatment could drive the share price up over 500% according to analysts at Liberum Capital, who on Monday initiated the stock with a ‘buy’ rating and 60p target price. In its initiation note, the ‘house’ broker for the AIM-listed pharma firm said they expected positive data from the Phase 3 trial for MED2002, which is expected to be delivered by December this year." So maybe November we will know the outcome.
j777j
19/6/2019
07:14
James Barder, Chief Executive Officer, Futura Medical said: "We are extremely pleased to complete recruitment of over 1,000 patients for the first European Phase 3 study, "FM57", of MED2005, within our expected timelines and budget and I would like to thank all parties involved in reaching this important milestone. The Company's focus is now on the Phase 3 data read-out at the end of the year, which we hope will significantly clinically de-risk MED2005, and help provide commercial partners with greater certainty around the potential opportunity it presents." The potential market for this product is large with potential peak sales in excess of US $1 billion. If MED2005 is approved, there is an estimated $560M prescription-only market potential (sources: Decision Resources and Cello), and an estimated incremental $660M+ market potential as an over-the-counter (OTC) product, in markets where switch is possible. (source: Ipsos Mori forecasts commissioned by Futura).
j777j
18/6/2019
17:01
Good old Grannypants always knows best.
j777j
17/6/2019
14:33
As my dear old gran used to tell me "all good things come to those that wait"
ragnarr
17/6/2019
13:27
Simply need US bio fund or two onboard and the shares will rerate.
j777j
Chat Pages: 676  675  674  673  672  671  670  669  668  667  666  665  Older
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190625 08:08:14